Priothera
  • Home
  • Science
    • Mocravimod
    • Acute Myeloid Leukemia & Hematopoietic Cell Transplantation
    • CAR T Cells
    • Our Pipeline
    • Publications
  • MO-TRANS
  • Press
  • About
    • Our Leadership Team
    • Advisory Board
    • Investors
    • Our Partners
    • ESG and Recognition
  • Contact
Select Page

mocravimod

by admin | Jun 16, 2022

Recent Posts

  • Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program
  • Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
  • Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
  • Innover pour mieux soigner – Les cancers du sang avec Priothera
  • PRIOTHERA révolutionne le standard des soins dans les thérapies cellulaires en hémato-oncologie

Recent Comments

  • Priothera to start Phase IIb/III trial of acute myeloid leukaemia therapy on Priothera Receives FDA clearance of Investigational New Drug (IND)
  • FDA grants orphan drug designation to mocravimod for acute myeloid leukemia - Healio - The Online Chemists on Priothera – FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)

Priothera, Adding Quality Years to Life

Get In Touch

Priothera SAS
57 Avenue Général de Gaulle
68300 Saint-Louis, France

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland

© Priothera Ltd. 2025

Priothera SAS
57 Avenue Général de Gaulle
68300 Saint-Louis, France

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland